Sedating cns-active drugs are typically studied for the potential to impair next-morning driving. Data from an on-road driving performance study are presented for lemborexant (lem), a dual orexin receptor antagonist under development for insomnia disorder.
|Number of pages||1|
|Issue number||Suppl. 1|
|Publication status||Published - 27 Apr 2018|
|Event||32nd Annual Meeting of the Associated Professional Sleep Societies, LLC - Baltimore, United States|
Duration: 2 Jun 2018 → 6 Jun 2018